IRadimed Corp (IRMD) stock
IRMDNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 19/3060% above fair value
$85.35+0.12 (+0.14%)
Close on Nov 13, 2026Market cap $1.09BP/E 45.6Yield –
Earnings
IRadimed's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
Feb 9, 2027
Q4 FY2026 · estimated, before the open
Revenue, Q3 FY2026
$24.20M
+14.2% on a year earlier
non-GAAP diluted EPS, Q3 FY2026
$0.55
$0.47 a year earlier
Latest guidance
Issued
Oct 30, 2026 · 6 items
Quarterly results
Revenue and earnings per share from each of IRadimed's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Adj. EPS | Source |
|---|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Feb 9, 2027Expected | – | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Oct 30, 2026before the open | $24.20M | +14.2% | $0.51 | $0.55 | Release |
| Q2 FY2026ended Jun 30, 2026 | Aug 18, 2026during market hours | $20.50M | +0.5% | $0.41 | $0.46 | Release |
| Q1 FY2026ended Mar 31, 2026 | May 1, 2026before the open | $22.00M | +12.8% | $0.45 | $0.49 | Release |
| Q4 FY2025ended Dec 31, 2025 | Feb 10, 2026before the open | $22.70M | +17.0% | $0.50 | $0.54 | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 3, 2025before the open | $21.20M | +15.8% | $0.43 | $0.47 | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 1, 2025before the open | $20.40M | +14.0% | $0.45 | $0.49 | Release |
| Q1 FY2025ended Mar 31, 2025 | May 5, 2025before the open | $19.50M | +10.8% | $0.37 | $0.42 | Release |
| Q4 FY2024ended Dec 31, 2024 | Feb 13, 2025before the open | $19.40M | +10.9% | $0.40 | $0.44 | Release |
| Q3 FY2024ended Sep 30, 2024 | Oct 31, 2024before the open | $18.30M | +10.9% | $0.40 | $0.43 | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 1, 2024before the open | $17.90M | +11.2% | $0.38 | $0.42 | Release |
| Q1 FY2024ended Mar 31, 2024 | May 2, 2024before the open | $17.60M | +13.5% | $0.32 | $0.36 | Release |
| Q4 FY2023ended Dec 31, 2023 | Feb 8, 2024before the open | $17.50M | +17.4% | $0.36 | $0.39 | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 3, 2023before the open | $16.50M | +23.1% | $0.40 | $0.43 | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 3, 2023before the open | $16.10M | +26.8% | $0.33 | $0.36 | Release |
| Q1 FY2023ended Mar 31, 2023 | May 4, 2023before the open | $15.50M | +26.0% | $0.27 | $0.30 | Release |
| Q4 FY2022ended Dec 31, 2022 | Feb 2, 2023during market hours | $14.90M | +25.2% | $0.29 | $0.32 | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 3, 2022before the open | $13.40M | +22.9% | $0.27 | $0.29 | Release |
| Q2 FY2022ended Jun 30, 2022 | Jul 29, 2022before the open | $12.70M | – | $0.26 | $0.26 | Release |
| Q1 FY2022ended Mar 31, 2022 | Apr 29, 2022before the open | $12.30M | – | $0.20 | $0.22 | Release |
| Q4 FY2021ended Dec 31, 2021 | Feb 4, 2022before the open | $11.90M | – | $0.31 | $0.33 | Release |
| Q3 FY2021ended Sep 30, 2021 | Oct 29, 2021before the open | $10.90M | – | $0.20 | $0.23 | Release |
| Q2 FY2021ended Jun 30, 2021 | Jul 30, 2021before the open | – | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | Apr 30, 2021before the open | – | – | – | – | Filing |
| Q4 FY2020ended Dec 31, 2020 | Feb 4, 2021before the open | – | – | – | – | Filing |
| Q3 FY2020ended Sep 30, 2020 | Oct 30, 2020before the open | – | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
IRadimed's latest outlook for periods it has not reported yet, compared with what it said before
| Metric | Period | Guidance | Before | Change | Given |
|---|---|---|---|---|---|
| revenue | Q4 FY2026 | $25.00M – $26.50M | – | New | Oct 30, 2026 |
| GAAP diluted earnings per shareGAAP | Q4 FY2026 | $0.53 – $0.57 | – | New | Oct 30, 2026 |
| non-GAAP diluted earnings per sharenon-GAAP | Q4 FY2026 | $0.57 – $0.61 | – | New | Oct 30, 2026 |
| revenue | FY2026 | $91.60M – $93.10M | – | New | Oct 30, 2026 |
| revenue | FY2026 | $91.00M – $96.00M | $91.00M – $96.00M | Reaffirmed | Aug 18, 2026 |
| GAAP diluted earnings per shareGAAP | FY2026 | $1.90 – $1.94 | – | New | Oct 30, 2026 |
| GAAP diluted earnings per shareGAAP | FY2026 | $1.90 – $2.05 | $1.90 – $2.05 | Reaffirmed | Aug 18, 2026 |
| non-GAAP diluted earnings per sharenon-GAAP | FY2026 | $2.07 – $2.11 | – | New | Oct 30, 2026 |
| non-GAAP diluted earnings per sharenon-GAAP | FY2026 | $2.09 – $2.24 | $2.06 – $2.21 | Raised | Aug 18, 2026 |
Guidance vs results
The last range IRadimed gave before each report, against the figure it then reported. Full years add up the four quarters.
| Period | Metric | Guidance | Actual | Result |
|---|---|---|---|---|
| Q3 FY2026 | EPS (GAAP) | $0.49 – $0.54 | $0.51 | Within range |
| Q3 FY2026 | non-GAAP diluted earnings per share | $0.54 – $0.59 | $0.55 | Within range |
| Q3 FY2026 | Revenue | $23.00M – $24.50M | $24.20M | Within range |
| Q2 FY2026 | EPS (GAAP) | $0.40 – $0.44 | $0.41 | Within range |
| Q2 FY2026 | non-GAAP diluted earnings per share | $0.44 – $0.48 | $0.46 | Within range |
| Q2 FY2026 | Revenue | $20.00M – $21.00M | $20.50M | Within range |
| Q1 FY2026 | EPS (GAAP) | $0.39 – $0.43 | $0.45 | Above range |
| Q1 FY2026 | non-GAAP diluted earnings per share | $0.44 – $0.48 | $0.49 | Above range |
| Q1 FY2026 | Revenue | $21.00M – $22.00M | $22.00M | Within range |
| FY2025 | EPS (GAAP) | $1.68 – $1.72 | $1.75Σ4Q | Above range |
| FY2025 | non-GAAP diluted earnings per share | $1.84 – $1.88 | $1.92Σ4Q | Above range |
| FY2025 | Revenue | $82.50M – $83.50M | $83.80MΣ4Q | Above range |
| Q4 FY2025 | EPS (GAAP) | $0.43 – $0.47 | $0.50 | Above range |
| Q4 FY2025 | non-GAAP diluted earnings per share | $0.47 – $0.51 | $0.54 | Above range |
| Q4 FY2025 | Revenue | $21.40M – $22.40M | $22.70M | Above range |
| Q3 FY2025 | EPS (GAAP) | $0.41 – $0.45 | $0.43 | Within range |
| Q3 FY2025 | non-GAAP diluted earnings per share | $0.45 – $0.49 | $0.47 | Within range |
| Q3 FY2025 | Revenue | $20.50M – $20.90M | $21.20M | Above range |
| Q2 FY2025 | EPS (GAAP) | $0.37 – $0.40 | $0.45 | Above range |
| Q2 FY2025 | non-GAAP diluted earnings per share | $0.41 – $0.44 | $0.49 | Above range |
| Q2 FY2025 | Revenue | $19.70M – $19.90M | $20.40M | Above range |
| Q1 FY2025 | EPS (GAAP) | $0.35 – $0.39 | $0.37 | Within range |
| Q1 FY2025 | non-GAAP diluted earnings per share | $0.39 – $0.43 | $0.42 | Within range |
| Q1 FY2025 | Revenue | $19.20M – $19.40M | $19.50M | Above range |
| Q4 FY2024 | EPS (GAAP) | $0.39 – $0.42 | $0.40 | Within range |
| Q4 FY2024 | Non-GAAP diluted earnings per share | $0.42 – $0.45 | $0.44 | Within range |
| Q4 FY2024 | Revenue | $18.80M – $19.20M | $19.40M | Above range |
| Q3 FY2024 | EPS (GAAP) | $0.34 – $0.37 | $0.40 | Above range |
| Q3 FY2024 | non-GAAP diluted earnings per share | $0.38 – $0.41 | $0.43 | Above range |
| Q3 FY2024 | Revenue | $18.00M – $18.20M | $18.30M | Above range |
| Q2 FY2024 | EPS (GAAP) | $0.33 – $0.36 | $0.38 | Above range |
| Q2 FY2024 | non-GAAP diluted earnings per share | $0.36 – $0.39 | $0.42 | Above range |
| Q2 FY2024 | Revenue | $17.60M – $17.80M | $17.90M | Above range |
| Q1 FY2024 | EPS (GAAP) | $0.29 – $0.31 | $0.32 | Above range |
| Q1 FY2024 | non-GAAP diluted earnings per share | $0.33 – $0.35 | $0.36 | Above range |
| Q1 FY2024 | Revenue | $17.00M – $17.30M | $17.60M | Above range |
| Q4 FY2023 | EPS (GAAP) | $0.35 – $0.38 | $0.36 | Within range |
| Q4 FY2023 | non-GAAP diluted earnings per share | $0.38 – $0.41 | $0.39 | Within range |
| Q4 FY2023 | Revenue | $16.90M – $17.40M | $17.50M | Above range |
| Q3 FY2023 | EPS (GAAP) | $0.33 – $0.35 | $0.40 | Above range |
| Q3 FY2023 | non-GAAP diluted earnings per share | $0.36 – $0.38 | $0.43 | Above range |
| Q3 FY2023 | Revenue | $16.10M – $16.30M | $16.50M | Above range |
| Q2 FY2023 | EPS (GAAP) | $0.27 – $0.29 | $0.33 | Above range |
| Q2 FY2023 | non-GAAP diluted earnings per share | $0.30 – $0.32 | $0.36 | Above range |
| Q2 FY2023 | Revenue | $15.60M – $15.80M | $16.10M | Above range |
| Q1 FY2023 | EPS (GAAP) | $0.23 – $0.25 | $0.27 | Above range |
| Q1 FY2023 | non-GAAP diluted earnings per share | $0.26 – $0.28 | $0.30 | Above range |
| Q1 FY2023 | Revenue | $14.60M – $14.90M | $15.50M | Above range |
| Q4 FY2022 | EPS (GAAP) | $0.23 – $0.28 | $0.29 | Above range |
| Q4 FY2022 | non-GAAP diluted earnings per share | $0.25 – $0.30 | $0.32 | Above range |
| Q4 FY2022 | Revenue | $14.10M – $14.80M | $14.90M | Above range |
| Q3 FY2022 | EPS (GAAP) | $0.21 – $0.24 | $0.27 | Above range |
| Q3 FY2022 | non-GAAP diluted earnings per share | $0.22 – $0.25 | $0.29 | Above range |
| Q3 FY2022 | Revenue | $13.10M – $13.30M | $13.40M | Above range |
| Q2 FY2022 | EPS (GAAP) | $0.21 – $0.23 | $0.26 | Above range |
| Q2 FY2022 | non-GAAP diluted earnings per share | $0.23 – $0.25 | $0.26 | Above range |
| Q2 FY2022 | Revenue | $12.50M – $12.70M | $12.70M | Within range |
| Q1 FY2022 | EPS (GAAP) | $0.16 – $0.18 | $0.20 | Above range |
| Q1 FY2022 | non-GAAP diluted earnings per share | $0.20 – $0.21 | $0.22 | Above range |
| Q1 FY2022 | Revenue | $12.10M – $12.30M | $12.30M | Within range |
| Q4 FY2021 | EPS (GAAP) | $0.17 – $0.18 | $0.31 | Above range |
| Q4 FY2021 | non-GAAP diluted earnings per share | $0.20 – $0.21 | $0.33 | Above range |
| Q4 FY2021 | Revenue | $11.50M – $11.70M | $11.90M | Above range |
Guidance history
Every forecast IRadimed put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| Oct 30, 2026 | non-GAAP diluted earnings per share | FY2026 | $2.07 – $2.11 | New |
| Oct 30, 2026 | non-GAAP diluted earnings per share | Q4 FY2026 | $0.57 – $0.61 | New |
| Oct 30, 2026 | GAAP diluted earnings per share | FY2026 | $1.90 – $1.94 | New |
| Oct 30, 2026 | GAAP diluted earnings per share | Q4 FY2026 | $0.53 – $0.57 | New |
| Oct 30, 2026 | revenue | Q4 FY2026 | $25.00M – $26.50M | New |
| Oct 30, 2026 | revenue | FY2026 | $91.60M – $93.10M | New |
| Aug 18, 2026 | non-GAAP diluted earnings per share | Q3 FY2026 | $0.54 – $0.59 | New |
| Aug 18, 2026 | non-GAAP diluted earnings per share | FY2026 | $2.09 – $2.24 | Raised |
| Aug 18, 2026 | GAAP diluted earnings per share | FY2026 | $1.90 – $2.05 | Reaffirmed |
| Aug 18, 2026 | GAAP diluted earnings per share | Q3 FY2026 | $0.49 – $0.54 | New |
| Aug 18, 2026 | revenue | FY2026 | $91.00M – $96.00M | Reaffirmed |
| Aug 18, 2026 | revenue | Q3 FY2026 | $23.00M – $24.50M | New |
| May 1, 2026 | non-GAAP diluted earnings per share | Q2 FY2026 | $0.44 – $0.48 | New |
| May 1, 2026 | non-GAAP diluted earnings per share | FY2026 | $2.06 – $2.21 | Reaffirmed |
| May 1, 2026 | GAAP diluted earnings per share | Q2 FY2026 | $0.40 – $0.44 | New |
| May 1, 2026 | GAAP diluted earnings per share | FY2026 | $1.90 – $2.05 | Reaffirmed |
| May 1, 2026 | revenue | Q2 FY2026 | $20.00M – $21.00M | New |
| May 1, 2026 | revenue | FY2026 | $91.00M – $96.00M | Reaffirmed |
| Feb 10, 2026 | non-GAAP diluted earnings per share | FY2026 | $2.06 – $2.21 | New |
| Feb 10, 2026 | non-GAAP diluted earnings per share | Q1 FY2026 | $0.44 – $0.48 | New |
| Feb 10, 2026 | GAAP diluted earnings per share | Q1 FY2026 | $0.39 – $0.43 | New |
| Feb 10, 2026 | GAAP diluted earnings per share | FY2026 | $1.90 – $2.05 | New |
| Feb 10, 2026 | revenue | Q1 FY2026 | $21.00M – $22.00M | New |
| Feb 10, 2026 | revenue | FY2026 | $91.00M – $96.00M | New |
| Nov 3, 2025 | non-GAAP diluted earnings per share | FY2025 | $1.84 – $1.88 | New |
| Nov 3, 2025 | non-GAAP diluted earnings per share | Q4 FY2025 | $0.47 – $0.51 | New |
| Nov 3, 2025 | GAAP diluted earnings per share | Q4 FY2025 | $0.43 – $0.47 | New |
| Nov 3, 2025 | GAAP diluted earnings per share | FY2025 | $1.68 – $1.72 | New |
| Nov 3, 2025 | revenue | Q4 FY2025 | $21.40M – $22.40M | New |
| Nov 3, 2025 | revenue | FY2025 | $82.50M – $83.50M | New |
| Aug 1, 2025 | non-GAAP diluted earnings per share | FY2025 | $1.76 – $1.86 | Raised |
| Aug 1, 2025 | non-GAAP diluted earnings per share | Q3 FY2025 | $0.45 – $0.49 | New |
| Aug 1, 2025 | GAAP diluted earnings per share | FY2025 | $1.60 – $1.70 | Raised |
| Aug 1, 2025 | GAAP diluted earnings per share | Q3 FY2025 | $0.41 – $0.45 | New |
| Aug 1, 2025 | revenue | FY2025 | $80.00M – $82.50M | Raised |
| Aug 1, 2025 | revenue | Q3 FY2025 | $20.50M – $20.90M | New |
| May 5, 2025 | non-GAAP diluted earnings per share | Q2 FY2025 | $0.41 – $0.44 | New |
| May 5, 2025 | non-GAAP diluted earnings per share | FY2025 | $1.71 – $1.81 | Reaffirmed |
| May 5, 2025 | GAAP diluted earnings per share | FY2025 | $1.55 – $1.65 | Reaffirmed |
| May 5, 2025 | GAAP diluted earnings per share | Q2 FY2025 | $0.37 – $0.40 | New |
| May 5, 2025 | revenue | Q2 FY2025 | $19.70M – $19.90M | New |
| May 5, 2025 | revenue | FY2025 | $78.00M – $82.00M | Reaffirmed |
| Feb 13, 2025 | non-GAAP diluted earnings per share | FY2025 | $1.71 – $1.81 | New |
| Feb 13, 2025 | non-GAAP diluted earnings per share | Q1 FY2025 | $0.39 – $0.43 | New |
| Feb 13, 2025 | GAAP diluted earnings per share | Q1 FY2025 | $0.35 – $0.39 | New |
| Feb 13, 2025 | GAAP diluted earnings per share | FY2025 | $1.55 – $1.65 | New |
| Feb 13, 2025 | revenue | Q1 FY2025 | $19.20M – $19.40M | New |
| Feb 13, 2025 | revenue | FY2025 | $78.00M – $82.00M | New |
| Oct 31, 2024 | Non-GAAP diluted earnings per share | FY2024 | $1.64 – $1.67 | Raised |
| Oct 31, 2024 | Non-GAAP diluted earnings per share | Q4 FY2024 | $0.42 – $0.45 | New |
| Oct 31, 2024 | GAAP diluted earnings per share | FY2024 | $1.49 – $1.52 | Raised |
| Oct 31, 2024 | GAAP diluted earnings per share | Q4 FY2024 | $0.39 – $0.42 | New |
| Oct 31, 2024 | revenue | FY2024 | $72.70M – $73.10M | Narrowed |
| Oct 31, 2024 | revenue | Q4 FY2024 | $18.80M – $19.20M | New |
| Aug 1, 2024 | non-GAAP diluted earnings per share | Q3 FY2024 | $0.38 – $0.41 | New |
| Aug 1, 2024 | non-GAAP diluted earnings per share | FY2024 | $1.52 – $1.62 | Reaffirmed |
| Aug 1, 2024 | GAAP diluted earnings per share | FY2024 | $1.37 – $1.47 | Reaffirmed |
| Aug 1, 2024 | GAAP diluted earnings per share | Q3 FY2024 | $0.34 – $0.37 | New |
| Aug 1, 2024 | revenue | FY2024 | $72.00M – $74.00M | Reaffirmed |
| Aug 1, 2024 | revenue | Q3 FY2024 | $18.00M – $18.20M | New |
| May 2, 2024 | non-GAAP diluted earnings per share | Q2 FY2024 | $0.36 – $0.39 | New |
| May 2, 2024 | non-GAAP diluted earnings per share | FY2024 | $1.52 – $1.62 | Reaffirmed |
| May 2, 2024 | GAAP diluted earnings per share | FY2024 | $1.37 – $1.47 | Reaffirmed |
| May 2, 2024 | GAAP diluted earnings per share | Q2 FY2024 | $0.33 – $0.36 | New |
| May 2, 2024 | revenue | FY2024 | $72.00M – $74.00M | Reaffirmed |
| May 2, 2024 | revenue | Q2 FY2024 | $17.60M – $17.80M | New |
| Feb 8, 2024 | non-GAAP diluted earnings per share | FY2024 | $1.52 – $1.62 | New |
| Feb 8, 2024 | non-GAAP diluted earnings per share | Q1 FY2024 | $0.33 – $0.35 | New |
| Feb 8, 2024 | GAAP diluted earnings per share | FY2024 | $1.37 – $1.47 | New |
| Feb 8, 2024 | GAAP diluted earnings per share | Q1 FY2024 | $0.29 – $0.31 | New |
| Feb 8, 2024 | revenue | FY2024 | $72.00M – $74.00M | New |
| Feb 8, 2024 | revenue | Q1 FY2024 | $17.00M – $17.30M | New |
| Nov 3, 2023 | non-GAAP diluted earnings per share | Q4 FY2023 | $0.38 – $0.41 | New |
| Nov 3, 2023 | non-GAAP diluted earnings per share | FY2023 | $1.48 – $1.51 | Raised |
| Nov 3, 2023 | GAAP diluted earnings per share | FY2023 | $1.34 – $1.37 | Raised |
| Nov 3, 2023 | GAAP diluted earnings per share | Q4 FY2023 | $0.35 – $0.38 | New |
| Nov 3, 2023 | revenue | Q4 FY2023 | $16.90M – $17.40M | New |
| Nov 3, 2023 | revenue | FY2023 | $65.00M – $65.50M | Raised |
| Aug 3, 2023 | non-GAAP diluted earnings per share | FY2023 | $1.37 – $1.40 | Raised |
| Aug 3, 2023 | non-GAAP diluted earnings per share | Q3 FY2023 | $0.36 – $0.38 | New |
| Aug 3, 2023 | GAAP diluted earnings per share | Q3 FY2023 | $0.33 – $0.35 | New |
| Aug 3, 2023 | GAAP diluted earnings per share | FY2023 | $1.25 – $1.28 | Raised |
| Aug 3, 2023 | revenue | Q3 FY2023 | $16.10M – $16.30M | New |
| Aug 3, 2023 | revenue | FY2023 | $64.50M – $65.50M | Raised |
| May 4, 2023 | non-GAAP diluted earnings per share | FY2023 | $1.26 – $1.35 | Raised |
| May 4, 2023 | non-GAAP diluted earnings per share | Q2 FY2023 | $0.30 – $0.32 | New |
| May 4, 2023 | GAAP diluted earnings per share | FY2023 | $1.13 – $1.21 | Raised |
| May 4, 2023 | GAAP diluted earnings per share | Q2 FY2023 | $0.27 – $0.29 | New |
| May 4, 2023 | revenue | FY2023 | $62.00M – $63.50M | Raised |
| May 4, 2023 | revenue | Q2 FY2023 | $15.60M – $15.80M | New |
| Feb 2, 2023 | non-GAAP diluted earnings per share | Q1 FY2023 | $0.26 – $0.28 | Reaffirmed |
| Feb 2, 2023 | non-GAAP diluted earnings per share | FY2023 | $1.23 – $1.34 | Reaffirmed |
| Feb 2, 2023 | GAAP diluted earnings per share | FY2023 | $1.10 – $1.20 | Reaffirmed |
| Feb 2, 2023 | GAAP diluted earnings per share | Q1 FY2023 | $0.23 – $0.25 | Reaffirmed |
| Feb 2, 2023 | revenue | FY2023 | $61.00M – $63.00M | Reaffirmed |
| Feb 2, 2023 | revenue | Q1 FY2023 | $14.60M – $14.90M | Reaffirmed |
| Jan 19, 2023 | non-GAAP diluted earnings per share | Q1 FY2023 | $0.26 – $0.28 | New |
| Jan 19, 2023 | non-GAAP diluted earnings per share | FY2023 | $1.23 – $1.34 | New |
| Jan 19, 2023 | GAAP diluted earnings per share | FY2023 | $1.10 – $1.20 | New |
| Jan 19, 2023 | GAAP diluted earnings per share | Q1 FY2023 | $0.23 – $0.25 | New |
| Jan 19, 2023 | revenue | FY2023 | $61.00M – $63.00M | New |
| Jan 19, 2023 | revenue | Q1 FY2023 | $14.60M – $14.90M | New |
| Nov 3, 2022 | non-GAAP diluted earnings per share | FY2022 | $1.03 – $1.08 | Raised |
| Nov 3, 2022 | non-GAAP diluted earnings per share | Q4 FY2022 | $0.25 – $0.30 | New |
| Nov 3, 2022 | full-year GAAP diluted earnings per share | FY2022 | $0.95 – $1.00 | Raised |
| Nov 3, 2022 | GAAP diluted earnings per share | Q4 FY2022 | $0.23 – $0.28 | New |
| Nov 3, 2022 | full-year revenue | FY2022 | $52.50M – $53.20M | Reaffirmed |
| Nov 3, 2022 | revenue | Q4 FY2022 | $14.10M – $14.80M | New |
| Jul 29, 2022 | non-GAAP diluted earnings per share | Q3 FY2022 | $0.22 – $0.25 | New |
| Jul 29, 2022 | non-GAAP diluted earnings per share | FY2022 | $0.96 – $1.03 | Reaffirmed |
| Jul 29, 2022 | GAAP diluted earnings per share | FY2022 | $0.89 – $0.95 | Reaffirmed |
| Jul 29, 2022 | GAAP diluted earnings per share | Q3 FY2022 | $0.21 – $0.24 | New |
| Jul 29, 2022 | revenue | FY2022 | $52.50M – $53.20M | Reaffirmed |
| Jul 29, 2022 | revenue | Q3 FY2022 | $13.10M – $13.30M | New |
| Apr 29, 2022 | non-GAAP diluted earnings per share | FY2022 | $0.96 – $1.03 | Raised |
| Apr 29, 2022 | non-GAAP diluted earnings per share | Q2 FY2022 | $0.23 – $0.25 | New |
| Apr 29, 2022 | GAAP diluted earnings per share | FY2022 | $0.89 – $0.95 | Raised |
| Apr 29, 2022 | GAAP diluted earnings per share | Q2 FY2022 | $0.21 – $0.23 | New |
| Apr 29, 2022 | revenue | FY2022 | $52.50M – $53.20M | Raised |
| Apr 29, 2022 | revenue | Q2 FY2022 | $12.50M – $12.70M | New |
| Feb 4, 2022 | non-GAAP diluted earnings per share | Q1 FY2022 | $0.20 – $0.21 | New |
| Feb 4, 2022 | non-GAAP diluted earnings per share | FY2022 | $0.91 – $1.01 | New |
| Feb 4, 2022 | GAAP diluted earnings per share | FY2022 | $0.82 – $0.90 | New |
| Feb 4, 2022 | GAAP diluted earnings per share | Q1 FY2022 | $0.16 – $0.18 | New |
| Feb 4, 2022 | revenue | FY2022 | $51.40M – $52.20M | New |
| Feb 4, 2022 | revenue | Q1 FY2022 | $12.10M – $12.30M | New |
| Oct 29, 2021 | non-GAAP diluted earnings per share | Q4 FY2021 | $0.20 – $0.21 | New |
| Oct 29, 2021 | non-GAAP diluted earnings per share | FY2021 | $0.70 – $0.71 | New |
| Oct 29, 2021 | GAAP diluted earnings per share | FY2021 | $0.60 – $0.61 | New |
| Oct 29, 2021 | GAAP diluted earnings per share | Q4 FY2021 | $0.17 – $0.18 | New |
| Oct 29, 2021 | revenue | FY2021 | $41.40M – $41.60M | New |
| Oct 29, 2021 | revenue | Q4 FY2021 | $11.50M – $11.70M | New |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases IRadimed filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- News
- Results
- Results
- News
- Results
- Update
- Results
- News
- Results
- Results
- IRADIMED CORPORATION Reports Preliminary Unaudited Record Fourth Quarter and Full-Year 2024 RevenuesResults
- Results
- Results
See a number that looks wrong?